|
WO2020248942A1
|
|
ANTI-β-NGF NANOBODY AND USE THEREFOR
|
|
WO2020248938A1
|
|
Anti-cd25 antibody and application thereof
|
|
WO2020248926A1
|
|
BIFUNCTIONAL FUSION PROTEIN AGAINST PDL1 AND TGFβ AND USE THEREOF
|
|
WO2020239005A1
|
|
Antibody or chimeric antigen receptor which targets claudin 18.2
|
|
WO2020239014A1
|
|
Anti-cgrp antibody and application thereof
|
|
CN111592597A
|
|
Interleukin 4 receptor (IL-4R) binding proteins and uses thereof
|
|
CN112062848A
|
|
anti-CD47 monoclonal antibody and application thereof
|
|
CN112062844A
|
|
anti-ANGPTL 3 antibodies and uses thereof
|
|
CN112010976A
|
|
anti-LAG3 antibodies and uses thereof
|
|
CN112010974A
|
|
Antibody specifically binding to human 4-1BB and application thereof
|
|
CN111273019A
|
|
Duraluvian peptide ELISA detection method
|
|
WO2019101196A1
|
|
Anti-pd-l1 antibody and use thereof
|
|
CN109929038A
|
|
The purification process of VEGF capturing agent fusion protein
|
|
CN109929027A
|
|
Using the recombination fusion protein purification process of linear elution step
|
